We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Coronavirus (COVID-19) Vaccine Approved for Clinical Trials in China

By HospiMedica International staff writers
Posted on 23 Mar 2020
Print article
Image: Coronavirus (COVID-19) vaccine approved for clinical trials in China (Photo courtesy of CanSino Biologics Inc.)
Image: Coronavirus (COVID-19) vaccine approved for clinical trials in China (Photo courtesy of CanSino Biologics Inc.)
CanSino Biologics Inc. (Hong Kong, China), a biopharmaceutical company focusing on vaccine R&D and commercialization, has received approval for its recombinant novel coronavirus vaccine (Adenovirus Type 5 Vector) candidate (Ad5-nCoV), co-developed with the Beijing Institute of Biotechnology (BIB), for beginning Phase 1 clinical trial. It is currently the first novel coronavirus vaccine for COVID-19 to make it to this stage in China.

CanSinoBIO possesses four integrated platform technologies, including adenovirus-based vectors, conjugation, protein design and recombination and formulation. It currently has a robust pipeline of 16 vaccines covering 13 diseases, including a globally innovative Ebola virus vaccine approved for marketing in 2017, as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector).

The recombinant novel coronavirus vaccine candidate is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform, which has also been successfully applied to develop the globally innovative vaccine against Ebola virus infection. Results from preclinical animal studies of Ad5-nCoV have shown that the vaccine candidate can induce strong immune response in animal models. The preclinical animal safety studies also demonstrated a good safety profile.

“Thanks to our collaborators and our diligent team, who worked almost around clock since late January to develop this vaccine candidate with sound scientific data to support IND filing,” said Xuefeng Yu, Chairman and CEO of CanSinoBIO, “Having committed to provide unconditional support to fight against the global epidemic, CanSinoBIO is determined to launch our vaccine product candidate as soon as possible with no compromise on quality and safety.”

Related Links:
CanSino Biologics Inc.

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
CT Phantom
CIRS Model 610 AAPM CT Performance Phantom

Print article

Channels

Surgical Techniques

view channel
Image: The ProScan AI assisted reading tool is designed to unlock the future of gastroenterology (Photo courtesy of AnX Robotica)

AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions

A revolutionary artificial intelligence (AI) technology that has proven faster and more accurate in diagnosing small bowel bleeding could transform gastrointestinal medicine. AnX Robotica (Plano, TX,... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more